The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tolerability and cardiac safety of neo/adjuvant trastuzumab-based chemotherapy regimens for HER2+ breast cancer: A single institution experience.
Potjana Jitawatanarat
No relevant relationships to disclose
Ellen Kossoff
No relevant relationships to disclose
Grazyna Riebandt
No relevant relationships to disclose
Ellis Glenn Levine
No relevant relationships to disclose
Tracey L. O'Connor
No relevant relationships to disclose
Kaweesak Chittawatanarat
No relevant relationships to disclose
Nuttapong Ngamphaiboon
No relevant relationships to disclose